Fig. 6: In vivo safety of CTCE-p53 NPs and the combination with anti-PD-1 antibody. | Nature Communications

Fig. 6: In vivo safety of CTCE-p53 NPs and the combination with anti-PD-1 antibody.

From: Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy

Fig. 6

a–k Serum biochemistry analysis (n = 4 samples for CTCE-EGFP NPs group; n = 5 samples for the left four groups). l–r Whole blood panel tests analysis (n = 5 samples for each group). All data are presented as mean ± S.E.M. Source data are provided as a Source Data file.

Back to article page